CSF2 and diffuse intrinsic pontine glioma: One phase I trial administered pelareorep, an immunomodulatory oncolytic virus, combined with sargramostin, a recombinant human granulocyte-macrophage colony-stimulating factor, in patients with progressive DIPG.